Tuesday, April 16, 2024

Cenobamate associated with lower inpatient days and ER visits

Treatment of Focal Epilepsy with Cenobamate Associated with Lower Inpatient Days and ER Visits Compared with 7 Leading Anti-Seizure Medications

The addition of cenobamate to the treatment regimens of people with focal epilepsy was associated with lower rates of inpatient days and emergency room (ER) visits compared with the addition of 7 other leading anti-seizure medications (ASMs). This finding, which was presented at the American Academy of Neurology (AAN) 2024 Annual Meeting, results from a retrospective claims-based analysis study of health care utilization outcomes. Each of the 7 other ASMs were associated with higher inpatient days and HR visitation rates compared with cenobamate, and this trend was consistent across focal epilepsy subgroups.

The study included data for 58,786 individuals from the HealthVerity Marketplace Private Source 20 database with diagnosed focal epilepsy who were taking at least 1 ASM between 2017 and 2021. The study population was exposed to 84,301 lines of therapy (LOT) in total, and researchers used mixed-effect regressions to evaluate statistical associations between epilepsy-associated inpatient days and ER visits and LOT adding cenobamate or 7 other ASMs, which included:







Fycompa (parempanel; Eisai, Nutley, NJ)

Participants experienced 170.6 inpatient days and 41.0 ER visits per 100 patient-years over 116,859.2 person years. Inpatient day and ER visitation rates for each of the 7 ASMs were higher than those of cenobamate (P≤.001). Per 100 patient-years, adjusted mean increases in inpatient days relative to cenobamate ranged from 1.7 for lamotrigine, to 6.4 for lacosamide. Compared with cenobamate, adjusted mean increases in ER visits ranged from 2.0 for brivaracetam, to 8.8 for levetiracetam, per 100 patient-years.

The study was conducted by investigators from the University of Pittsburgh School of Medicine, SK Life Science, and Epilogix.


No comments:

Post a Comment